Lilly sues two medical spas over copycat weight-loss drugs
Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound.
Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected
Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue guidance down 5%,
Eli Lilly: Still Much Room To Ride The Weight-Loss Wave
Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Eli Lilly’s stock was set to suffer its worst day in four years after sales of diabetes and obesity drugs Mounjaro and Zepbound missed expectations.
NVO, VKTX Stocks Fall as Lilly's Zepbound, Mounjaro Sales Slow Down
Popular obesity stocks fell on Tuesday after pharma giant Eli Lilly LLY lowered its sales guidance for full-year 2024 and announced disappointing preliminary fourth-quarter sales numbers. LLY’s Revised ’24 Sales View Below Expectations Eli Lilly anticipates fourth-quarter revenues to reach approximately $13.
S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook Weakens
Key Takeaways The S&P 500 added 0.1% on Tuesday, Jan. 14, as tame wholesale inflation data provided a positive signal ahead of Wednesday's consumer price report.Eli Lilly shares plunged after the pharma giant cut its sales guidance,
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those results unsettled investors, setting off a three-week sello
JD Supra18h
Lilly v. FDA: Two Stories Collide to Make this GLP-1 Case a Tale of Our Time
I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...
Ibj.com27d
Lilly stock caught up in wave of uncertainty
“The demand for Lilly products continues to be very robust, and the stock continues to look strong longer-term despite some near-term volatility,” they wrote. “Periods of consolidation are ...
Eli Lilly & Co: Strong Long-Term Growth Prospects Amid Q4 Revenue Shortfall Justify Buy Rating
Bank of America Securities analyst Tim Anderson maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...
Baltimore City school system sues drug companies over allegedly inflated price of insulin
The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...
Opinion
BioSpace12dOpinion
Opinion: Why Is Novo Outperforming Lilly Despite Having Inferior GLP-1 Products?
Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...
Eli Lilly & Co: Strong Growth Prospects and Strategic Investments Justify Buy Rating
Eli Lilly & Co (LLY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Geoff Meacham ...
Has Eli Lilly Stock Peaked?
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...